BACKGROUND: Sexual dysfunction is a distressing long-term effect after gynecological cancer and affects the majority of survivors for years after the completion of therapy. Despite its prevalence, treatment-related sexual dysfunction is underrecognized and undertreated for survivors. Thus, the aim of this study was to develop and test a brief psychoeducational intervention for managing sexual dysfunction for women who have undergone treatment for ovarian cancer (OC). METHODS:Forty-six OC survivors with documented, treatment-related sexual dysfunction received a single half-day group intervention that included sexual health education and rehabilitation training, relaxation and cognitive behavioral therapy skills to address sexual symptoms, and a single tailored booster telephone call 4 weeks after the group. Assessment measures were completed at the baseline (baseline 1), after an 8-week no-treatment run-in period (baseline 2), and then again 2 and 6 months after the intervention. The Female Sexual Function Index (FSFI) was used to assess sexual functioning, and the Brief Symptom Inventory 18 (BSI-18) was used to capture psychological distress. RESULTS: Between baseline 1 and baseline 2, there were no significant changes in the study measures, and this indicated no natural improvement during the run-in period. In contrast, the total FSFI scores improved significantly from baseline 1 to the 2- (n = 45; P < .0005) and 6-month time points (n = 42; P < .05). The BSI-18 scores were also significantly improved at the 2- (P < .005) and 6-month time points (P < .01) in comparison with baseline 1. CONCLUSIONS: This brief behavioral intervention led to significant improvements in overall sexual functioning and psychological distress that were maintained at the 6-month follow-up. The results demonstrate the feasibility of this brief, low-intensity behavioral intervention and support the development of a larger randomized controlled trial. Cancer 2018;124:176-82.
RCT Entities:
BACKGROUND:Sexual dysfunction is a distressing long-term effect after gynecological cancer and affects the majority of survivors for years after the completion of therapy. Despite its prevalence, treatment-related sexual dysfunction is underrecognized and undertreated for survivors. Thus, the aim of this study was to develop and test a brief psychoeducational intervention for managing sexual dysfunction for women who have undergone treatment for ovarian cancer (OC). METHODS: Forty-six OC survivors with documented, treatment-related sexual dysfunction received a single half-day group intervention that included sexual health education and rehabilitation training, relaxation and cognitive behavioral therapy skills to address sexual symptoms, and a single tailored booster telephone call 4 weeks after the group. Assessment measures were completed at the baseline (baseline 1), after an 8-week no-treatment run-in period (baseline 2), and then again 2 and 6 months after the intervention. The Female Sexual Function Index (FSFI) was used to assess sexual functioning, and the Brief Symptom Inventory 18 (BSI-18) was used to capture psychological distress. RESULTS: Between baseline 1 and baseline 2, there were no significant changes in the study measures, and this indicated no natural improvement during the run-in period. In contrast, the total FSFI scores improved significantly from baseline 1 to the 2- (n = 45; P < .0005) and 6-month time points (n = 42; P < .05). The BSI-18 scores were also significantly improved at the 2- (P < .005) and 6-month time points (P < .01) in comparison with baseline 1. CONCLUSIONS: This brief behavioral intervention led to significant improvements in overall sexual functioning and psychological distress that were maintained at the 6-month follow-up. The results demonstrate the feasibility of this brief, low-intensity behavioral intervention and support the development of a larger randomized controlled trial. Cancer 2018;124:176-82.
Authors: Bernadine Cimprich; Nancy K Janz; Laurel Northouse; Patricia A Wren; Barbara Given; Charles W Given Journal: Psychooncology Date: 2005-09 Impact factor: 3.894
Authors: Saketh R Guntupalli; Jeanelle Sheeder; Yevgeniya Ioffe; Ana Tergas; Jason D Wright; Susan A Davidson; Kian Behbakht; Dina M Flink Journal: Int J Gynecol Cancer Date: 2017-03 Impact factor: 3.437
Authors: Ciska Buijs; Constantijne H Mom; Pax H B Willemse; H Marike Boezen; J Marina Maurer; A N Machteld Wymenga; Robert S de Jong; Peter Nieboer; Elisabeth G E de Vries; Marian J E Mourits Journal: Breast Cancer Res Treat Date: 2008-08-01 Impact factor: 4.872
Authors: Katrina F Trivers; Jennifer Rees Patterson; Katherine B Roland; Juan L Rodriguez Journal: Support Care Cancer Date: 2013-07-12 Impact factor: 3.603
Authors: Dominique Frechette; Lise Paquet; Shailendra Verma; Mark Clemons; Paul Wheatley-Price; Stan Z Gertler; Xinni Song; Nadine Graham; Susan Dent Journal: Breast Cancer Res Treat Date: 2013-08-14 Impact factor: 4.872
Authors: Michelle E Melisko; Mindy E Goldman; Jimmy Hwang; Amy De Luca; Sally Fang; Laura J Esserman; Amy J Chien; John W Park; Hope S Rugo Journal: JAMA Oncol Date: 2017-03-01 Impact factor: 31.777
Authors: Areej El-Jawahri; Sarah R Fishman; Julie Vanderklish; Don S Dizon; Nicole Pensak; Lara Traeger; Joseph A Greer; Elyse R Park; Netana Markovitz; Lauren Waldman; Chrisa Hunnewell; Meredith Saylor; Jessica Driscoll; Zhigang Li; Thomas R Spitzer; Steven McAfee; Yi-Bin Chen; Jennifer S Temel Journal: Cancer Date: 2018-03-14 Impact factor: 6.860
Authors: Atun Raudotul Ma'rifah; Yati Afiyanti; Mega Hasanul Huda; Roselyn Chipojola; Yelmi Reni Putri; M A Tantawi Nasution Journal: Support Care Cancer Date: 2022-07-12 Impact factor: 3.359
Authors: Mackenzi Pergolotti; Antoine Bailliard; Lauren McCarthy; Erica Farley; Kelley R Covington; Kemi M Doll Journal: Am J Occup Ther Date: 2020 May/Jun